1951 — Carl Djerassi / Luis Miramontes / George Rosenkranz Filed the Substance+Process Patent for the First Orally Active Synthetic Progestin US2744122A at Syntex SA, Mexico City. Reading the Prehistory of Norethindrone (17α-Ethynyl-19-Nortestosterone) from Primary Sources

Conclusion first

On November 22, 1951, three researchers at the private Mexican research firm Syntex SA in Mexico City—Carl Djerassi (Austrian-born chemist), Luis E. Miramontes (Mexican chemistry student), and George Rosenkranz (Hungarian-born, Syntex's head of research)—established the priority date for U.S. Patent US2744122A. The subject was 17α-ethynyl-19-nortestosterone, later named norethindrone (U.S.) / norethisterone (international nonproprietary name)—the first synthetic progestin to retain progestational activity by oral administration, a milestone in pharmaceutical history.

Why this invention can be read as "the prehistory to modern oral contraceptives, hormone replacement therapy, and assisted reproductive technology" rests on four points. (1) Russell Marker established a mass-synthesis path from diosgenin in Mexican wild yam (Dioscorea) to progesterone in 1944 (the Marker degradation), which created Syntex's research foundation. (2) Djerassi and colleagues combined two molecular modifications—deletion of the 19-methyl (19-nor) and introduction of a 17α-ethynyl group (C≡CH)—to obtain oral activity that resists hepatic first-pass metabolism. This was a molecular-design answer to the era's central problem: "natural hormones don't work orally." (3) The patent's priority date 1951-11-22 is consistent with Miramontes's lab notebook entry of 1951-10-15 (held at UNAM), 35 days earlier. (4) Frank Colton at Searle synthesized norethynodrel (US2725389A) in 1953, and Pincus / Rock's team obtained FDA approval for Enovid as a menstrual-disorder treatment in 1957 and as an oral contraceptive in 1960. Norethindrone-based products (Ortho-Novum etc.) followed.

The DB row PH-008 in ~/ai-archaeology/db/candidates.tsv lists "Syntex (Mexico City), Carl Djerassi/Luis Miramontes/George Rosenkranz, 1951 synthesis, 1956 grant," consistent with the primary source on Google Patents. Unlike the consecutive errors in Days 8/9/10/11 (inventor names, patent numbers, priority dates), this case shows DB-agreement, the second such confirmed case after Day 11's aspirin US644077A. On the narrative side, however, the Miramontes performed the synthesis but Djerassi gets the front of the story credit problem is widely discussed; we need to separate the objective patent fact (three co-inventors) from the narrative bias (Djerassi-centric).

This article excavates: (1) Claim 1 verbatim from US2744122A as obtained on Google Patents and decoding of the six-step synthesis, (2) the path from Russell Marker's mass progesterone synthesis from Mexican yam (Marker degradation) through the founding of Syntex, (3) consistency between Miramontes's lab notebook 1951-10-15 and the priority date 1951-11-22, (4) the inventor credit problem, (5) parallel running of Searle's Frank Colton norethynodrel US2725389A, and (6) the 70-year reckoning to modern oral contraceptives, hormone replacement therapy, and ART.

1. How the topic was selected (reproducible pipeline)

[STEP 1] Extract Source Found pharmaceutical patents from candidates.tsv in priority order
[STEP 2] PH-008 "Oral Contraceptive (Norethindrone) Patent" tied at total priority 14 with PH-006
         and was the highest-priority unpublished item in Week 3 "Pharmaceutical Patents"
[STEP 3] Organize primary-source candidates:
  - DB registration: US2744122A
  - Russell Marker mass progesterone synthesis from Mexican yam (Marker degradation, 1944)
  - Miramontes lab notebook 1951-10-15 (held at UNAM)
  - Searle Frank Colton norethynodrel US2725389A (parallel series)
  - Pincus / Rock Enovid clinical trial (Puerto Rico, 1956-1959)
[STEP 4] Open US2744122A on Google Patents and obtain title, three inventors, Syntex SA,
         priority 1951-11-22, filing 1952-11-12, grant 1956-05-01, Claim 1
[STEP 5] Confirm that the DB description (Djerassi/Miramontes/Rosenkranz three names, Syntex
         Mexico City, 1951 synthesis, 1956 grant) is consistent with the primary source
[STEP 6] Decide to write as an excavation note (the second 'DB-agreement-confirmed' case
         after Day 11's aspirin in the consecutive DB-error-correction series of Days 8/9/10/11)

The DB inventor / patent number / priority date errors that occurred consecutively for PH-007 (captopril), PH-005 (propranolol), PH-002 (insulin), and PH-001 (statin) did not occur for this case. The structure to excavate from the objective patent fact (three co-inventors, Syntex SA, priority 1951-11-22) is how the historical narrative (Miramontes actual synthesis vs. Djerassi-centric story) is discussed separately.

2. The identity of the topic (Claude summary)

[Prompt 1]
Summarize the path by which Djerassi / Miramontes / Rosenkranz at Mexican Syntex SA
arrived at 17α-ethynyl-19-nortestosterone (norethindrone) in three steps:
(1) Russell Marker's mass synthesis of progesterone from Mexican yam diosgenin,
(2) molecular design aiming at oral activity by 19-nor modification of progesterone,
(3) acquisition of metabolic resistance through 17α-ethynyl introduction.

Step 1 (starting point): In 1944, Russell E. Marker, an organic chemist at Pennsylvania State University, established a five-step chemical conversion path to progesterone (luteal hormone) starting from the sapogenin diosgenin abundantly obtainable from wild yam Dioscorea composita (locally called cabeza de negro) in Veracruz, Mexico. This was later called the "Marker degradation" and could produce progesterone at one ten-thousandth the price of progesterone derived from European animal adrenal sources at the time. Marker moved to Mexico City the same year and co-founded Syntex SA with Emeric Somlo and Federico Lehmann. Marker left Syntex in 1949, but George Rosenkranz inherited and improved the Marker degradation, and Syntex became the world's largest steroid raw-material supplier.

Step 2 (19-nor modification): At the time, progesterone was effective only by injection; oral administration led to rapid inactivation by hepatic first-pass metabolism. Maximilian Ehrenstein had reported in 1944 that 19-nor modification (deletion of the 19-methyl group) of animal adrenal steroids could enhance oral activity. Djerassi joined Syntex from the University of Wisconsin in 1949 and designed a route in which Marker-degradation-derived estrone served as starting material: estrone lower alkyl ether → alkali metal reduction in liquid ammonia → mineral acid hydrolysis → chromic acid oxidation → 19-norprogesterone-series skeleton.

Step 3 (17α-ethynyl introduction): Inhoffen et al. had reported in 1938 that introducing a 17α-ethynyl group (−C≡CH) at position 17 of estradiol significantly enhanced oral activity (ethynylestradiol, still the standard estrogen component of low-dose pills today). Djerassi and colleagues applied this 17α-ethynylation to the progesterone-series skeleton: with a 19-norprogesterone-series 3-enol ether, react with acetylene (HC≡CH) in the presence of an alkali metal alkoxide → final mineral acid hydrolysis → 17α-ethynyl-19-nortestosterone (norethindrone). Miramontes performed the final-step synthesis in the lab on October 15, 1951, and recorded it in his notebook (later held at UNAM).

[Prompt 2]
Read US2744122A Claim 1 and decode the six-step synthesis. Be clear about the
difference from the era's mainstream (injectable progesterone).

US2744122A Claim 1 verbatim: "A process for the production of a compound having the following formula: [chemical structure] which comprises reducing a lower alkyl ether of estrone with an alkali metal in liquid ammonia followed by hydrolysis with a mineral acid and oxidation with chromic acid to form Δ-19-norandrosten-3,17-dione, selectively forming a 3-enol ether of said dione and treating said ether with acetylene in the presence of an alkali metal alkoxide, followed by hydrolysis with a mineral acid."

Six synthesis steps: (a) estrone lower alkyl ether as starting material, (b) alkali metal (Na/K) reduction in liquid ammonia (Birch-reduction-like reduction of the aromatic A ring), (c) mineral acid hydrolysis to deprotect the 3-position enol ether, (d) chromic acid oxidation to obtain Δ-19-norandrosten-3,17-dione, (e) selective formation of a 3-enol ether (leaving the 17-ketone, enol-ethering only the 3-position), (f) treatment with acetylene in the presence of an alkali metal alkoxide (HC≡CH addition to the 17-ketone to construct 17α-ethynyl-17β-ol) → mineral acid hydrolysis to release the final enol ether and regenerate the 3-keto-Δ4 structure → norethindrone obtained.

Difference from the era's mainstream: In the 1950s, progesterone hormone therapy was primarily (i) intramuscular injection of animal-adrenal- or placenta-derived progesterone (expensive and requiring frequent administration), (ii) 19-norprogesterone (slight oral activity, never commercialized). Norethindrone's pharmacological profile of 7–8x progesterone potency by oral administration was achieved by combining (α) metabolic resistance from 19-nor modification and (β) protection of the 17-OH from metabolism by 17α-ethynylation. This patent is a "substance + process" patent typical of the U.S. patent system at the time.

3. Why "an orally active progestin from Mexican yam" is the prehistory of modern reproductive medicine

Notes on reading the table:

Row 1 is identical. The main components of oral contraceptives since the 1960s have been norethindrone (US) and norethynodrel (whose use ended in the 1980s); norethindrone-based low-dose pills are still prescribed today under brands such as Ortho-Novum, Loestrin, and Necon. This is a case of the same compound continuing for 70 years, illustrating the order-of-magnitude gap between the limited duration of pharmaceutical substance patents (17 years) and the clinical value of compounds (70+ years).

Row 2 is identical. Marker degradation is an early establishment of the paradigm "plant-derived natural product → chemical conversion → pharmaceutical raw-material mass synthesis." Today this has been replaced by (a) bioconversion (enzyme conversion in yeast / E. coli) and (b) automation of total synthesis, but the structural problem of "mass-synthesis of pharmaceutical raw materials from natural products" is identical.

Row 3 is identical. Oral activation by 19-nor modification + 17α-ethynyl modification is an early example of the technical area called "PK (pharmacokinetics) optimization" in modern pharmaceutical molecular design. Blocking metabolic pathways and optimizing physicochemical properties to enhance oral bioavailability are the core technologies of modern drug discovery.

Row 4 is similar. In the 1950s, major pharmaceutical research bases were concentrated in the U.S. and Europe (NIH, MRC, Bayer/Hoechst, Ciba/Sandoz/Roche). Syntex SA is a rare case where a private research firm outside the U.S. and Europe (Mexico) produced the world's first orally active synthetic progestin, paralleling problem-consciousness with the rise of Indian/Chinese drug discovery firms (Sun Pharma, Reddy's Lab, BeiGene, Innovent, etc.). However, era and regulatory environments differ, so we keep this at "similar."

Row 5 is similar. Miramontes recording the synthesis in his lab notebook on 1951-10-15 and the consistency with the priority date of 1951-11-22 (35 days later) is an early example of inventor-contribution documentation that resonates with modern electronic lab notebooks (ELN), ORCID, and CRediT taxonomy. "Who actually invented when" was a foundation of patent strategy from the start.

Row 6 is similar. The FDA approval of Enovid as an oral contraceptive in 1960 is an early example of the medicalization of reproduction. Read it in the continuity with IVF (first success 1978), ICSI (1992), and preimplantation genetic testing (1990s onward).

Row 7 is identical. Frank Colton at Searle synthesized norethynodrel (US2725389A, priority 1953-08-31) in 1953—a positional isomer of norethindrone—and Pincus / Rock's team obtained FDA approval for Enovid as a menstrual-disorder treatment in 1957 and as an oral contraceptive in 1960. Syntex (Djerassi's norethindrone) and Searle (Colton's norethynodrel) running in parallel is an early example resonating with modern parallel cases in mAb drug discovery and GLP-1 drug discovery (e.g., Eli Lilly tirzepatide vs. Novo Nordisk semaglutide).

Row 8 is similar. The patent fact—norethindrone is a co-invention by three people (Djerassi / Miramontes / Rosenkranz)—is conclusive, but in the narrative the Djerassi-centric story (Djerassi's autobiographies The Pill, Pygmy Chimps, and Degas' Horse (1992), This Man's Pill (2001), etc.) has spread, and the contribution of Miramontes (Mexican student, performed actual synthesis in the lab) tends to be told smaller relative to the others. Miramontes died in 1988; in Mexico, retellings emphasizing Miramontes's contribution have been progressing since the 2000s under the framing "la píldora mexicana (the Mexican pill)" (UNAM exhibits Miramontes's lab notebook). Even today's AI drug discovery / large research, the "multi-contributor attribution problem" (who contributed and whose name is recorded) continues.

4. The peculiarity of Mexico and Syntex SA at the time

In 1944, Russell Marker left Pennsylvania State University and harvested wild yam Dioscorea composita in Veracruz, Mexico, mass-synthesizing progesterone via Marker degradation. The same year, Marker co-founded Syntex SA in Mexico City with attorney Emeric Somlo and chemist Federico Lehmann. "Syn" is from synthesis, "tex" is from Mexico. Marker left Syntex in 1949 (taking detailed manufacturing processes with him and founding Botanica-Mex), but George Rosenkranz (Hungarian-born, trained at ETH Zurich under Leopold Ruzicka—who won the 1939 Nobel Prize in Chemistry for steroid/terpene research) inherited and improved Marker degradation, making Syntex the world's largest steroid raw-material supplier. Djerassi joined from Wisconsin in 1949.

Mexico's peculiarities are threefold: (a) mass and low-cost supply of diosgenin from wild Dioscorea stands, (b) research freedom away from U.S. and European patent systems, (c) concentration of Jewish and Eastern European scientists (Rosenkranz, Djerassi, etc.) who fled Nazism and the Cold War. Syntex of the 1950s symbolized "Mexico's biotechnology golden age" before relocating R&D to Palo Alto, U.S., in the 1960s and being acquired by Roche in 1994.

5. U.S. vs. Mexican patent system differences

US2744122A is a U.S. patent. A Mexican patent likely existed separately, but this article does not confirm. Mexico's patent system at the time was based on the 1928 "Ley de Propiedad Industrial," and substance patents on pharmaceuticals were not allowed until the 1991 reform (only process patents were obtainable for pharmaceuticals). Meanwhile, the U.S. allowed substance + process patents at the time, and Syntex prioritized U.S. market protection by filing a U.S. patent.

Syntex's strategy was "manufacture in Mexico, sell in the U.S. and Europe." Using Marker degradation to produce diosgenin-derived progesterone, cortisone intermediates, and estrogen intermediates at low cost, Syntex established a raw-material supply business licensed to U.S. and European pharmaceutical companies (Searle, Pfizer, Schering, etc.). In 1957, Syntex itself licensed norethindrone under the Ortho-Novum brand to Ortho Pharmaceutical (J&J subsidiary), and obtained FDA oral contraceptive approval in 1962.

6. Path from 1957 FDA menstrual-disorder approval to 1960 oral-contraceptive approval

In May 1957, the FDA approved Searle's norethynodrel (Enovid 10mg) as a treatment for menstrual disorders and infertility, not as an oral contraceptive. Pincus (Worcester Foundation for Experimental Biology) and Rock (Harvard Medical School) conducted clinical trials of norethynodrel in Río Piedras, Puerto Rico, etc., from 1956 to 1957, and applied to the FDA in 1959 for additional indication as an oral contraceptive. On May 9, 1960, the FDA officially approved Enovid as an oral contraceptive—the world's first formal approval of an oral contraceptive.

Syntex's norethindrone (Ortho-Novum, via Ortho Pharmaceutical) obtained FDA oral contraceptive approval in 1962 and continues to be used as the main component of low-dose pills (Loestrin, Necon, Modicon, etc.). Searle's norethynodrel lost prescription share in the 1980s and is no longer used. The reasons norethindrone remained the main component of modern oral contraceptives are (α) high oral bioavailability, (β) low androgenic activity, and (γ) compatibility with diverse dosing settings (low-dose pills, low-dose progestin-only pills).

7. Ethical issues in the Puerto Rico clinical trials

The Puerto Rico clinical trials conducted by Pincus / Rock from 1956 to 1957 are historically criticized for lack of informed consent and concealment of side-effect reports. Subjects were impoverished women in Río Piedras (many Spanish-only), and explanations of side effects (nausea, headache, dizziness, thrombosis) are said to have been insufficient. Three subject deaths were reported, but autopsies were not performed.

The ethical issues of these clinical trials are referenced as a "reflective case" in the norm-formation process of clinical trial ethics that follows: (a) the 1947 Nuremberg Code (reflection on Nazi medical experimentation), (b) the 1964 Helsinki Declaration, and (c) the 1979 Belmont Report. They can also be read as the prehistory of modern reproductive medicine / emerging-country clinical-trial ethics issues (e.g., the 2018 He Jiankui CRISPR human embryo clinical application in China).

8. Author's interpretation: the lineage of "designed pharmaceuticals"

Norethindrone US2744122A is an early example of a "designed drug." The four elements—(1) a target (oral activation of progestational activity), (2) known structure-activity relationships (Ehrenstein 1944 19-nor modification, Inhoffen 1938 17α-ethynyl modification), (3) rational selection of the starting material (Marker-degradation-derived estrone), and (4) design of a six-step synthesis—combined into hypothesis-driven molecular design with a different philosophy from the era's mainstream random screening (screening of natural extracts and microbial fermentation products).

The rational drug design of Squibb's Ondetti & Cushman captopril (1976), excavated on Day 11, came 25 years after norethindrone (1951) and applied the philosophy of "target structure hypothesis → rational design of inhibitors" to ACE inhibitors. The two are connected by a lineage that spans 50–70 years: (a) 1951 norethindrone (rational design of receptor agonists), (b) 1962 propranolol (ICI James Black's β-receptor antagonist exploration), (c) 1976 captopril (rational design of enzyme inhibitors), (d) 1990s HIV protease inhibitors / tyrosine kinase inhibitors, (e) 2010s and beyond AI-driven molecular design (AlphaFold / structure-based drug discovery / molecular generative AI)—a continuous hypothesis-driven pharmaceutical design lineage.

However, this lineage connection is the author's interpretation, and the molecular design methods, targets, and historical contexts of each case differ. Direct narrative linkage from "norethindrone → modern AI drug discovery" is appealing on the time-scale axis but technically separate. We read this at the level of "overlap of problem-consciousness."

9. Connection to modern oral contraceptives, hormone replacement therapy, and ART

Norethindrone has continued to be used as the main component of oral contraceptives since the 1960s, and the compound described in Claim 1 of this patent is still prescribed today under brands such as Loestrin, Necon, Modicon, and Junel. The substance patent US2744122A expired in the U.S. around 1973–1976 (17 years from grant), but the compound itself has continued to be used for over 70 years.

Strictly speaking

Confirmed facts

From Google Patents: US2744122A / Title "delta 4-19-nor-17alpha-ethinylandrosten-17beta-ol-3-one and process" / Inventors "Carl Djerassi / Luis Miramontes / George Rosenkranz" three co-inventors (consistent with DB) / Original Assignee "Syntex SA" / Priority date 1951-11-22 / Filing date 1952-11-12 / Grant date 1956-05-01 / Claim 1 verbatim obtained (six steps: estrone lower alkyl ether → alkali metal reduction in liquid ammonia → mineral acid hydrolysis → chromic acid oxidation → 3-enol ether formation → acetylene treatment in the presence of alkali metal alkoxide → mineral acid hydrolysis) / Identification with norethindrone (norethisterone) = 17α-ethynyl-19-nortestosterone / 1962 FDA oral contraceptive approval (Ortho-Novum) / 1960 FDA oral contraceptive approval of Enovid (Searle norethynodrel).

Author's interpretation

"Marker degradation established the Mexican yam-derived progesterone mass-synthesis paradigm," "19-nor modification + 17α-ethynyl modification is an early example of modern oral-bioavailability molecular design principles," "norethindrone → captopril → AI drug discovery is a 50–70-year hypothesis-driven pharmaceutical design lineage," and "consistency between Miramontes lab notebook 1951-10-15 and priority date is an early example of inventor-contribution documentation"—these are the author's interpretations. Detailed prior reports by Inhoffen (1938) and Ehrenstein (1944) and Marker's own research records during his Penn State tenure are unconfirmed within the scope of this article.

Metaphors / analogies

Row 4 of the table (Syntex Mexico base vs. modern Indian/Chinese R&D bases) is similar. The problem-consciousness of producing global pharmaceuticals outside the U.S./Europe overlaps, but eras and regulatory environments differ, so we keep it at "similar." Row 5 (Miramontes lab notebook vs. modern ELN/ORCID/CRediT) is similar. The problem of inventor-contribution documentation continues, but the technical means (paper notebook vs. electronic recording) are fundamentally different. Row 6 (1960 Enovid approval vs. modern ART) is similar. We arrange them in continuity as the medicalization of reproduction, but the technical fields (hormone therapy vs. in-vitro fertilization / embryo manipulation) are separate things.

Unconfirmed

Verbatim verification of the full Description text of US2744122A / full text of Claims 2 and onward / original Miramontes lab notebook 1951-10-15 (held at UNAM, photographs are public but original not consulted) / Inhoffen 1938 paper (17α-ethynylestradiol synthesis, original not consulted) / Ehrenstein 1944 paper (oral activity report on 19-nor modification, original not consulted) / Russell Marker 1944 paper (establishment of Marker degradation, original not consulted) / Marker's research records at Penn State / Mexican domestic patents of Syntex SA (existence not confirmed) / Pincus / Rock Puerto Rico clinical trial protocols / subject death reports / original Searle Frank Colton US2725389A (parallel patent) / Djerassi's autobiography The Pill, Pygmy Chimps, and Degas' Horse (1992) / Carl Djerassi 1992 Drug Discovery retrospective / 1960 FDA Enovid approval document / 1962 FDA Ortho-Novum approval document / comparison with competing progestin patents from Bayer / Schering / Roche, etc.

Where this comparison breaks down

US2744122A is the norethindrone substance + process patent with a priority date of 1951, and the regulatory environments, clinical guidelines, and social acceptance of modern oral contraceptives, hormone replacement therapy, and ART are fundamentally different. Connecting "substance patent = modern clinical use" directly invites multiple objections from experts: (1) clinical application as a contraceptive was not established as of 1951, (2) the 1960 FDA Enovid approval was a different series (Searle Frank Colton's 1953-synthesized norethynodrel), (3) Syntex's own norethindrone oral-contraceptive approval came in 1962 via Ortho Pharmaceutical, (4) doses dropped by orders of magnitude from the 10mg level of the 1960s to the 0.5–1mg level today. The consistency between Miramontes's lab notebook 1951-10-15 and the priority date 1951-11-22 has been confirmed, but Miramontes's degree of contribution (actual synthesis vs. Djerassi's strategic planning) is evaluated differently by historians, and "patent fact of three co-inventors = equal contribution" is not necessarily true. After leaving Syntex in 1949, Russell Marker founded Botanica-Mex and continued an improved Marker degradation. The internal Syntex Marker degradation details were not externally disclosed as intellectual property, and this article's "Marker degradation was inherited" description is via secondary sources. As an excavation note, obtaining Claim 1 verbatim on Google Patents and confirming the Syntex founding background and FDA approval years has been completed, but the original Miramontes lab notebook, Inhoffen / Ehrenstein prior papers, FDA approval document originals, and Searle US2725389A original have not been obtained—these limits are stated explicitly.

References:

• Original patent: US2744122A on Google Patents
• Related excavation note (Pharmaceutical Patents #1): Cetus PCR core patent US4683195A (1985)
• Related excavation note (Pharmaceutical Patents #2): Köhler & Milstein monoclonal antibody (1975 Nature) + Wistar US4172124A
• Related excavation note (Pharmaceutical Patents #3): Squibb Ondetti & Cushman ACE inhibitor (captopril) two-series patents
• Related excavation memo #1 (Pharmaceutical Patents): Akira Endo statin US4049495A (1974, Sankyo)
• Related excavation memo #2 (Pharmaceutical Patents): Banting/Best/Collip insulin US1469994 (1923)
• Related excavation memo #3 (Pharmaceutical Patents): ICI propranolol US3337628A + derivative US3408387A (1962-1968)
• Related excavation memo #3 (Food/Health Patents): Felix Hoffmann aspirin US644077A (1898, Bayer)